

## **THE DOG ATE MY DACLATASVIR: REAL LIFE EXPERIENCES DELIVERING DIRECT ACTING ANTIVIRALS TO MARGINALISED, HOMELESS, AND ACTIVE DRUG USERS AT THE KIRKETON ROAD CENTRE**

R Gilliver<sup>1</sup>, R Lothian<sup>1</sup>, KJ Chronister<sup>1,2</sup>, W Machin<sup>1</sup>, J Kearley<sup>1</sup>, P Read<sup>1,2</sup>

<sup>1</sup> Kirketon Road Centre, South Eastern Sydney Local Health District, Sydney

<sup>2</sup> Kirby Institute, UNSW Australia, Sydney

**Introduction and Aims:** KRC is a publicly-funded primary health care service in Kings Cross. KRC provides prevention, treatment and care of viral hepatitis with a focus on people who currently inject drugs. Many studies of direct acting antivirals (DAAs) do not include those with current uncontrolled drug use. The aim of this study was to report the outcomes for the first cohort of active injecting drug users treated in the era of DAAs at KRC in a real life setting.

**Design and Methods:** All clients initiating DAA treatment were included. Demographics, drug use history and clinical outcomes were obtained from the clinical database. SVR12 will be compared for clients with ongoing injection drug use compared to those not currently using.

**Results:** Of 47 clients (mean age=46) who initiated DAAs to date, 31 are male, 11 are Aboriginal, and 13 were homeless. Thirty clients reported recent injecting drug use and 10 clients are currently on OST. Overall, 58% had no/mild fibrosis (F0/1), 9% moderate fibrosis (F2), and 9% had cirrhosis (F4). Among these clients, 44% were genotype 1a, 6% genotype 1b, 2% genotype 2b, and 48% were genotype 3a. Multiple options for treatment provision, support, and medication administration were required to ensure adherence in this population.

**Discussion and Conclusions:** This cohort of active injecting drug users reflect the experience of treating marginalised clients in a real world setting using an integrated primary health care model. This is a particularly important population to successfully treat from a public health perspective.

**Disclosure of Interest:** The authors have no conflicts of interest to declare.